Ovarian Cancer Research Alliance Community Partner

RSS News

  • FDA Places PC14586, for Cancers with Mutant Protein, on Fast Track October 22, 2020
    The U.S. Food and Drug Administration (FDA) has granted fast track designation to PC14586 as a potential treatment of advanced cancers that harbor a specific mutation affecting the protein p53, which includes some ovarian cancers. Fast track is given to support therapies with the potential to fill a serious unmet medical need. They are eligible […]
  • Phase 1 Trial of SL-172154 in Treating Advanced Ovarian Cancer Opens October 20, 2020
    Shattuck Labs has opened a Phase 1 clinical trial to investigate its lead candidate, SL-172154, in treating people with advanced ovarian cancer, the company announced in a press release. The trial (NCT04406623) is recruiting up to 33 patients at three sites in the U.S.: the John Wayne Cancer Institute at Providence St. John’s Health Center in California, […]
  • First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC October 15, 2020
    The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of resistant ovarian cancer. The new partnership was developed to test ZEN-3694 across several cancer indications. For this upcoming […]
  • OCRA Partners With Microsoft AI Initiative to Accelerate Ovarian Cancer Research October 13, 2020
    The Ovarian Cancer Research Alliance (OCRA) has partnered with Microsoft‘s AI for Health initiative, with the ultimate goal of accelerating ovarian cancer research using data science and artificial intelligence (AI). AI is a broad term that encompasses any use of a computer to accomplish tasks, from sorting to making complex decisions, that are usually associated […]
  • Lab-Grown 3D Tumor Model Provides New Tool to Study Ovarian Cancer, Treatments October 8, 2020
    A lab-grown, three-dimensional (3D) ovarian tumor model will give researchers a new way to study tumor growth in ovarian cancer and to test how tumors might respond to treatments, scientists say. The proof-of-concept study, “Peptide-protein coassembling matrices as a biomimetic 3D model of ovarian cancer,” was published in the journal Science Advances. Preclinical studies of […]
  • Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show October 6, 2020
    When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of disease progression compared to a placebo, according to five-year data from a Phase 3 trial. Updated findings from the study, called SOLO-1 (NCT01844986), were presented […]
  • Fertility-sparing Surgery Can Effectively Treat Borderline Ovarian Tumors, Study Shows October 1, 2020
    Fertility-sparing surgery can effectively treat borderline ovarian tumors (BOTs), while preserving a woman’s ability to conceive and bear children, a new study suggests. The study, “Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study,” was published in Fertility and […]
  • STRO-002 Trial Update Supports Its Safety, Activity in Advanced Cancer September 29, 2020
    Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily pre-treated women with advanced ovarian cancer. About one-quarter of patients receiving a dose of 2.9 mg/kg or higher responded to this investigational antibody-drug conjugate, and nearly half (44%) had responses lasting at least 16 weeks, results showed. […]
  • Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer September 24, 2020
    Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. The positive opinion released by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, also includes […]
  • CHMP Favors Zejula as First-line Maintenance Therapy for Platinum-sensitive Advanced Ovarian Cancer September 22, 2020
    The Committee for Medicinal Products for Human Use (CHMP) has recommended Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy. This favorable opinion by the committee, a branch of the European Medicines Agency (EMA), is one of the final steps of Zejula’s marketing authorization procedure that may lead to […]
  • Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study September 17, 2020
    Compass Therapeutics‘ CTX-2026, an antibody targeting the protein BTN3A1, could be therapeutic in ovarian cancer by helping the immune system destroy cancer cells, preclinical data show. The study, “BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells,” was published in the journal Science. The body’s immune system is responsible for fighting off infections […]
  • Newk’s Cares Honors Late Co-founder Lori Newcomb During Awareness Month September 15, 2020
    Newk’s Cares is honoring the legacy of co-founder Lori Newcomb this September during Ovarian Cancer Awareness Month with fundraising initiatives online and at the more than 100 Newk’s Eatery restaurants. Newk’s Cares is the philanthropic arm of Newk’s Eatery, the Jackson, Mississippi-based fast-casual restaurant chain. It was established in 2014, a year after Newcomb, an […]
  • Pap Smear Samples May Aid Early Diagnosis of Common Ovarian Cancer September 10, 2020
    Genetic material collected in routine cervical cancer screenings could be used to screen for ovarian cancer several years before disease symptoms are evident, possible speeding diagnosis and treatment, a study suggests. The study, “Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis,” was […]
  • National Ovarian Cancer Coalition Readies ‘Together in Teal’ Virtual Fundraiser September 8, 2020
    The National Ovarian Cancer Coalition (NOCC) is hosting its annual Together in Teal — No Boundaries fundraiser as a nationwide virtual celebration on Sept. 26, it announced in a press release. Presented during National Ovarian Cancer Awareness Month, the event raises money to support early disease awareness, quality of life for survivors, scientific research, and community […]
  • Research Alliance Hopes to Raise $200K During Awareness Month September 3, 2020
    The Ovarian Cancer Research Alliance (OCRA) is hoping to raise $200,000 in this year’s awareness month campaign to help fund research and support those with the disease, the organization announced. OCRA, the largest non-government funder of ovarian cancer research, is urging people worldwide to make single or monthly donations, which can be dedicated in memory […]